Polynovo Ltd traded at 0.88 this Wednesday March 4th, decreasing 0.03 or 2.76 percent since the previous trading session. Looking back, over the last four weeks, Polynovo lost 11.56 percent. Over the last 12 months, its price fell by 37.14 percent. Looking ahead, we forecast Polynovo Ltd to be priced at 0.92 by the end of this quarter and at 0.86 in one year, according to Trading Economics global macro models projections and analysts expectations.
PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.